ClinicalTrials.Veeva

Menu
U

University of Miami | Bascom Palmer Eye Institute

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ranibizumab
APL-2
LX201
AU-011
GT005
Pegcetacoplan
Ripasudil
Bevacizumab
Linsitinib
Lidocaine

Parent organization

This site is a part of University of Miami

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

19 of 95 total trials

A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1) (ASTRA)

This Phase 1/2 study will evaluate the safety, tolerability, and preliminary efficacy of subretinal SB-007 administration to determine dose selection...

Enrolling
Stargardt Macular Degeneration
Stargardt Disease
Genetic: SB-007

The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eye...

Enrolling
X-Linked Retinitis Pigmentosa (XLRP)
Biological: Adeno-associated virus vector expressing a human RPGR gene

Phase 2/3 Pivotal Confirmatory Clinical Trial is a randomized, outcome assessor-masked, multicenter study, that will enroll fifty-one (51) subjects....

Enrolling
Stargardt Disease
Drug: OCU410ST

The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twi...

Active, not recruiting
Thyroid Diseases
Graves Ophthalmopathy
Drug: Placebo
Drug: Linsitinib

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary i...

Enrolling
Indeterminate Lesions
Ocular Melanoma
Device: Suprachoroidal Microinjector
Drug: Bel-sar

This Phase 2 study is a non-randomized, open-label, study of the safety of AGTC-501 in participants with XLRP who have previously been treated with a...

Invitation-only
X-Linked Retinitis Pigmentosa
Biological: AGTC-501 (high dose and modified corticosteroid regimen)
Biological: AGTC-501 (high dose and standard corticosteroid regimen)

This study aims to evaluate the efficacy, safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of efgartigimod P...

Enrolling
Thyroid Eye Disease
Other: Placebo PH20 SC
Combination Product: Efgartigimod PH20 SC

This study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specifi...

Active, not recruiting
HER2-positive Breast Cancer
Drug: T-DM1
Drug: tucatinib

A study to assess the safety and efficacy of K-321 in participants with FECD after descemetorhexis.

Active, not recruiting
Fuchs Endothelial Corneal Dystrophy
Drug: Ripasudil
Drug: Placebo

Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight...

Enrolling
Thyroid Eye Disease
Other: Placebo
Drug: TOUR006 - 50 MG

A study to assess the safety and efficacy of K-321 in participants with FECD after simultaneous cataract surgery and descemetorhexis.

Active, not recruiting
Fuchs Endothelial Corneal Dystrophy
Drug: Placebo
Drug: Ripasudil

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: PEGCETACOPLAN (APL-2)

This study will evaluate the safety and tolerability of ATSN-201 in male subjects ≥ 6 years of age with RS1-associated X-linked retinoschisis (XLRS).

Enrolling
X-linked Retinoschisis
Biological: ATSN-201

The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were...

Enrolling
Thyroid Diseases
Graves Ophthalmopathy
Drug: linsitinib

In this early feasibility trial the safety and performance of the new retinal prothesis PRIMA is tested in five subjects suffering from atrophic dry...

Active, not recruiting
Dry Age-related Macular Degeneration
Device: PRIMA

The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of EDIT-101 administered via subretinal i...

Active, not recruiting
Eye Diseases, Hereditary
Inherited Retinal Dystrophies
Drug: EDIT-101

This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human cl...

Enrolling
Cone Rod Dystrophy
Stargardt Disease
Drug: ACDN-01

The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary carci...

Enrolling
Eye Cancer
Primary Cancer
Device: SCS Microinjector
Device: Laser

This is a double-masked, randomized, parallel-assignment, multicenter trial examining the safety and tolerability of teprotumumab in the treatment of...

Active, not recruiting
Thyroid Eye Disease
Drug: Teprotumumab
Drug: Placebo

Trial sponsors

University of Miami logo
Amgen logo
Astellas logo
National Institutes of Health (NIH) logo
A
A
C
Jaeb Center for Health Research logo
Aura Biosciences logo
B

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems